SU11248 for 2nd-line treatment of gastrointestinal stromal tumour (GIST) in patients refractory or intolerant of imatinib mesylate - horizon scanning review
National Horizon Scanning Centre
Record ID 32005000230
English
Authors' objectives:
This study aims to assess the effectiveness of SU11248 for 2nd-line treatment of gastrointestinal stromal tumour (GIST) in patients refractory or intolerant of imatinib mesylate.
Authors' recommendations:
SU11248 is the first in a new class of oral tyrosine kinase inhibitors, which target both tumour replication and angiogensis. It is currently in a phase III, randomised, placebo-controlled trial in patients who have failed or are intolerant of imatinib mesylate (Glivec, Gleevec), for whom there is currently no alternative treatment. One phase II trial in 92 patients demonstrated a partial response in 7 patients (8%), and stable disease was achieved in 53 patients (58%). Median time to progression was 34 weeks (range 3 to 94 weeks). Median survival in the overall cohort had not been reached when the data was presented.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.pcpoh.bham.ac.uk/publichealth/horizon/
Year Published:
2005
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein-Tyrosine Kinases
- Gastrointestinal Neoplasms
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.